Association of intestinal exfoliome and Prevotellaceae with toxicity and clinical outcome during immune-checkpoint blockade.

G Giacomo Vitali (MetaGenoPolis, INRAE, Paris-Saclay University, Jouy-En-Josas, France) C Carolina Alves Costa Silva D Dina Oudabi (INRAE, Jouy-En-Josas, France) C Cinzia Ungolo (Gustave Roussy, Villejuif, Ile-de-France, France) B Bryan Arlunno (Gustave Roussy Cancer Campus, Villejuif, France) A Adele Bonato (Section of Oncology, Department of Engineering for Innovation Medicine (DIMI), University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy) L Lorenzo Belluomini Y Yohann Loriot (Université Paris-Saclay, Gustave Roussy, INSERM Unité Mixte de Recherche 981 — Prédicteurs Moléculaires et Nouvelles Cibles en Oncologie, Villejuif, France) L Laurence Albiges (Department of Medical Oncology Gustave Roussy Villejuif France) B Bertrand Routy D David Planchard B Benjamin Besse L Laurence Zitvogel L Lisa Derosa (Gustave Roussy)

Abstract

2664 Background: Immune-related adverse events (irAEs) are autoimmune side effects related to ICI, varying in severity, onset and organ involvement that may be hard to differentiate from non-irAEs. Some reports have demonstrated that gut microbiota (GM) plays a role in modulating the risk of AEs. In this study, we combine gut mamalian and microbial metagenomics sequencing (MGS) to explore the influence of GM on treatment response and risk of AEs. Methods: NCT04567446 allowed fecal MGS at baseline and longitudinally in patients (pts) with advanced non-small cell lung cancer (), renal cell carcinoma and bladder cancer treated with ICI alone (ICI cohort, n = 542pts) or in combination with chemotherapy (CT+ICI cohort, n = 122 pts) in France and Canada. Pts who experienced severe (≥ grade 3) irAEs after ICI+/-CT were compared to those who did not, using microbial MGS parameters (Shannon diversity, TOPOSCORE, PCoA and LEfSe). Multivariate Cox regression models to analyze factors influencing overall survival (OS) included microbiota composition and the host exfoliome (i.e., mammalian eukaryotic DNA read counts within stools). Results: Pts with severe irAEs (10%) presented a less diverse microbiome, a lower TOPOSCORE and a distinct microbial community compared to those without severe irAEs, showing an overabundance of several members of the Prevotellaceae family. Interestingly, CT+ICI pts who experienced severe irAEs had the most dysbiotic microbiome, characterized by a lower alpha-diversity and TOPOSCORE, dominated by oral taxa ( Ligilactobacillus salivarius) and tolerogenic Hungatella spp. and Enterocloster spp. Among pts screened for exfoliation, 44% presented hstool mammalian DNA than healthy subjects, showed a GM enriched with pathobionts, including the Enterocloster genus, and exhibited worse OS (HR 1.212, p = 0.0135) in univariate and multivariate analyses (HR 1.18, p = 0.049). Although there was no significant correlation between toxicity and exfoliation, either in CT+ICI or ICI alone, pts enriched with Prevotellaceae family appeared to exhibit the highest levels of exfoliation. Conclusions: Host-microbial interactions influence immunity and therefore ICI prognosis and toxicity. We found Prevotellaceae members as potential biomarkers for ICI-related toxicity. The host exfoliome is an interesting parameter that may reflect gut fitness, requiring further investigation. Clinical trial information: NCT04567446 .

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
Pages 2664-2664
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (14)

G

Giacomo Vitali

MetaGenoPolis, INRAE, Paris-Saclay University, Jouy-En-Josas, France

C

Carolina Alves Costa Silva

D

Dina Oudabi

INRAE, Jouy-En-Josas, France

C

Cinzia Ungolo

Gustave Roussy, Villejuif, Ile-de-France, France

B

Bryan Arlunno

Gustave Roussy Cancer Campus, Villejuif, France

A

Adele Bonato

Section of Oncology, Department of Engineering for Innovation Medicine (DIMI), University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy

L

Lorenzo Belluomini

Y

Yohann Loriot

Université Paris-Saclay, Gustave Roussy, INSERM Unité Mixte de Recherche 981 — Prédicteurs Moléculaires et Nouvelles Cibles en Oncologie, Villejuif, France

L

Laurence Albiges

Department of Medical Oncology Gustave Roussy Villejuif France

B

Bertrand Routy

D

David Planchard

B

Benjamin Besse

L

Laurence Zitvogel

L

Lisa Derosa

Gustave Roussy